Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).
第一作者:
C Michael,Gibson
第一单位:
Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address: charlesmichaelgibson@gmail.com.
作者:
医学主题词
女(雌)性(Female);人类(Humans);男(雄)性(Male);急性冠状动脉综合征(Acute Coronary Syndrome);投药, 口服(Administration, Oral);临床试验, Ⅲ期(主题)(Clinical Trials, Phase III as Topic);双盲法(Double-Blind Method);因子Ⅺa(Factor XIa);出血(Hemorrhage);心肌梗死(Myocardial Infarction);血小板聚集抑制剂(Platelet Aggregation Inhibitors);随机对照试验(主题)(Randomized Controlled Trials as Topic);三唑类(Triazoles)
DOI
10.1016/j.ahj.2025.02.011
PMID
39986336
发布时间
2025-04-15
- 浏览2
American heart journal
21-28页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



